Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Management of Moderate to Severe Pain Clear all
Completed Phase 2 Interventional Results available

A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients

NCT02272634
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
YPL-001 80 mg, YPL-001 160 mg, Placebo
Drug
Lead sponsor
Yungjin Pharm. Co., Ltd.
Industry
Eligibility
30 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • Winter Park, Florida • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea

NCT03276936
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
FMX103 1.5%
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
79
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 72 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 3 Interventional Results available

An Open-label, 8-week Safety, Efficacy, and Assessment of Cooling Methods for Administration of CNTX-4975-05 for Knee OA

NCT03661996
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
CNTX-4975-05, Lidocaine without epinephrine, ElastoGel, Breg Ice Water Pump
Drug · Device
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
40 Years to 95 Years
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
28
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 3 Interventional

Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients

NCT01016808
View directory record Official record
Conditions
Moderate to Severe Postoperative Pain
Interventions
Q8003, Morphine sulfate, Oxycodone HCl
Drug
Lead sponsor
QRxPharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Anaheim, California • Owings Mills, Maryland • Pasadena, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Sep 25, 2026, 10:54 PM EDT
Completed No phase listed Observational

Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis

NCT05344482
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Secukinumab
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 3 Interventional Results available

Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis

NCT00658788
View directory record Official record
Conditions
Psoriasis
Interventions
clobetasol propionate spray 0.05%, calcitriol ointment
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 80 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
San Diego, California • Newnan, Georgia • Snellville, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

NCT02815280
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FMX-101, 4% minocycline foam, Vehicle Foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
9 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
35
States / cities
Glendale, Arizona • Rogers, Arkansas • Oceanside, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 1 Interventional Results available

A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose

NCT03250182
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT010
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)

NCT03259087
View directory record Official record
Conditions
Renal Impairment
Interventions
MK-3866
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Sep 25, 2026, 10:54 PM EDT
Terminated Phase 4 Interventional Results available

Pediatric Ketamine Study for Pain Management

NCT02388321
View directory record Official record
Conditions
Pain
Interventions
Ketamine, Fentanyl
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
3 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Sep 25, 2026, 10:54 PM EDT
Recruiting Phase 4 Interventional

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

NCT07228221
View directory record Official record
Conditions
Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions
iStent infinite trabecular micro-bypass system model iS3, iDose TR (Travoprost intracameral Implant) 75mcg
Device · Drug
Lead sponsor
Jonathon Myers
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 25, 2026, 10:54 PM EDT
Withdrawn Phase 1 Interventional

Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis and Crohn's Disease

NCT03414788
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
PF 06687234, [124I]IB PF 06687234
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Sep 25, 2026, 10:54 PM EDT
Terminated Phase 3 Interventional

Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

NCT01818076
View directory record Official record
Conditions
Skin Aging
Interventions
Botulinum Toxin Type A
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers

NCT01924676
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2015 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 4 Interventional

Changes to Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Prasterone in Women With Dyspareunia

NCT03568604
View directory record Official record
Conditions
Dyspareunia
Interventions
Prasterone
Drug
Lead sponsor
San Diego Sexual Medicine
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma

NCT01311661
View directory record Official record
Conditions
Asthma
Interventions
Placebo twice daily, Olodaterol low daily dose twice daily, Olodaterol medium daily dose twice daily, Olodaterol high daily dose once daily and placebo, Olodaterol medium daily dose once daily and placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
12
States / cities
Huntington Beach, California • Centennial, Colorado • Wheat Ridge, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered Naltrexone

NCT01456507
View directory record Official record
Conditions
Healthy
Interventions
ALO-02 (Oxycodone Naltrexone)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Sep 25, 2026, 10:54 PM EDT
Terminated Phase 4 Interventional Results available

Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)

NCT00608777
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Calcipotriene/betamethasone
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Sep 25, 2026, 10:54 PM EDT
Not listed Phase 2 Interventional

Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

NCT04163419
View directory record Official record
Conditions
Schwannomatosis, Pain
Interventions
Tanezumab, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Sep 25, 2026, 10:54 PM EDT
Completed No phase listed Observational Results available

TARGET Post-Approval Study

NCT02800863
View directory record Official record
Conditions
Complex Regional Pain Syndrome (CRPS)
Interventions
Dorsal Root Ganglion (DRG) Stimulation (Axium™ Neurostimulator System), Dorsal Root Ganglion (DRG) Stimulation (Proclaim™ Neurostimulator System)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
22 Years to 75 Years
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
44
States / cities
Scottsdale, Arizona • Camarillo, California • Larkspur, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2024 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 2 Interventional

Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients

NCT00831051
View directory record Official record
Conditions
Postoperative Pain
Interventions
Q8003, Morphine sulfate, Oxycodone HCl, Oxycodone HCl 4mg
Drug
Lead sponsor
QRxPharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Phoenix, Arizona • Anaheim, California • Owings Mills, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 3 Interventional Results available

Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.

NCT03108482
View directory record Official record
Conditions
Acute Post-surgical Pain
Interventions
Co-crystal E-58425 (Tramadol/Celecoxib), Tramadol (Ultram®), Celecoxib (Celebrex®), Placebo
Drug
Lead sponsor
Esteve Pharmaceuticals, S.A.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00968825
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 60 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Sep 25, 2026, 10:54 PM EDT
Terminated Phase 2 Interventional Results available

Doxycycline in Treating Patients With Chronic Rhinosinusitis With Nasal Polyps

NCT02569437
View directory record Official record
Conditions
Polyp of Nasal Sinus
Interventions
Doxycycline, methylprednisolone, nasal saline spray, Flonase, sugar pill
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Sep 25, 2026, 10:54 PM EDT